logo
Twitter
Discord
Email
logo
Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

NASDAQ•DRUG
CEO: Mr. Ian McDonald
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-03-22
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Contact Information
19 Vestry Street, New York, NY, 10013, United States
N/A
brightmindsbio.com
Market Cap
$685.26M
P/E (TTM)
-72.0
38.2
Dividend Yield
--
52W High
$123.75
52W Low
$23.18
52W Range
64%
Rank54Top 78.1%
2.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.30+141.18%
4-Quarter Trend

FCF

-$661.20K+96.56%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

FY2025 40-F Filed Annual Report filed for fiscal year ended September 30, 2025, incorporating required audited financial statements and MD&A exhibits.
Share Count Confirmed Confirmed 7,635,789 common shares outstanding as of the September 30, 2025 period close date for reporting purposes.
Internal Controls Effective Management evaluation confirmed disclosure controls and financial reporting controls were effective as of September 30, 2025.
NASDAQ Listed Security Common Shares trade on NASDAQ Capital Market under symbol DRUG; Company operates as a foreign private issuer.

Risk Factors

Financial Data External Key financial performance metrics are not detailed here, relying entirely on incorporated exhibits like the MD&A and AIF.
IFRS vs US GAAP Financial statements prepared under IFRS standards, which differ from US GAAP, impacting direct comparability for US investors.
Forward-Looking Statements Risk Forward-looking statements involve known and unknown risks; actual future results could materially differ from expectations.
Governance Disclosure Reliance NASDAQ compliance relies on Canadian home country practice accommodations for executive sessions and committee composition rules.

Outlook

Governance Structure Maintained Audit, Compensation, and N&CG Committees maintain full independence status based on NASDAQ Rule 5605 criteria for all members.
EGC Status Benefits Company remains an Emerging Growth Company, thus exempt from providing auditor attestation for internal control over financial reporting.
No Material Amendments No material amendment was made to the adopted Code of Business Conduct and Ethics during the fiscal year 2025.
CSE Compliance Intent Company intends to follow CSE rules regarding shareholder approval for dilutive issuances and fundamental change transactions.

Peer Comparison

Revenue (TTM)

Rigel Pharmaceuticals, Inc.RIGL
$282.08M
+79.1%
ADC Therapeutics SAADCT
$75.21M
+6.4%
Eton Pharmaceuticals, Inc.ETON
$70.32M
+102.8%

Gross Margin (Latest Quarter)

Alumis Inc.ALMS
100.0%
+0.0pp
Rigel Pharmaceuticals, Inc.RIGL
93.2%
+7.7pp
ADC Therapeutics SAADCT
92.7%
-2.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ALMS$2.49B-10.1-75.5%7.7%
DRUG$685.26M-72.0-19.8%0.1%
RIGL$680.31M6.0204.7%25.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 12, 2026
|
EPS:-$0.98
|
Revenue:-
Reports
All Years

  • Form 40-F - FY 2025

    Period End: Sep 30, 2025|Filed: Dec 23, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.92-96.9%
    N/A

  • Form 20-F - FY 2024

    Period End: Sep 30, 2024|Filed: Dec 31, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.48+67.2%
    N/A

  • Form 20-F - FY 2023

    Period End: Sep 30, 2023|Filed: Dec 29, 2023|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.47+67.8%
    N/A

  • Form 20-F - FY 2022

    Period End: Sep 30, 2022|Filed: Dec 29, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-4.81-29.7%
    N/A

  • Form 20-F/A - FY 2021

    Period End: Sep 30, 2021|Filed: Jan 18, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.75-1147.4%
    N/A

  • Form 20-F - FY 2021

    Period End: Sep 30, 2021|Filed: Dec 29, 2021|Refer to amended data